| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TRHC | Common Stock | Disposed to Issuer | -61.5K | -20.22% | 243K | Nov 3, 2023 | Direct | F1 | ||
| transaction | TRHC | Common Stock | Disposed to Issuer | -37K | -15.27% | 206K | Nov 3, 2023 | Direct | F2 | ||
| transaction | TRHC | Common Stock | Disposed to Issuer | -150K | -72.97% | 55.6K | Nov 3, 2023 | Direct | F3 | ||
| transaction | TRHC | Common Stock | Disposed to Issuer | -55.6K | -100% | 0 | Nov 3, 2023 | Direct | F4 |
Thomas Cancro is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among Tabula Rasa HealthCare, Inc. (the "Company"), Locke Buyer, LLC and Locke Merger Sub, Inc., dated August 5, 2023 (the "Merger Agreement"), 61,500 shares of common stock of the Company ("Common Stock") were converted into the right to receive a cash payment of $645,750, representing the product obtained by multiplying (x) aggregate number of shares of Common Stock owned by the reporting person, by (y) the offer price ($10.50). |
| F2 | Upon the consummation of the Merger, pursuant to the Merger Agreement, 37,037 outstanding restricted stock units ("RSUs") were cancelled and converted into the right to receive a cash payment of $388,888.50, representing the product obtained by multiplying (x) the aggregate number of shares of common stock of the Company ("Common Stock") underlying the RSUs, by (y) the offer price ($10.50). |
| F3 | Upon the consummation of the Merger, pursuant to the Merger Agreement, 150,000 unvested restricted stock awards ("RSAs") were cancelled and converted into the right to receive a cash payment of $1,575,000, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock underlying the RSAs, by (y) the offer price ($10.50). |
| F4 | Represents 55,555 shares of Common Stock underlying performance stock units ("PSUs") that were vested as of immediately prior to the effective time of the Merger but not yet settled or that automatically vested as a result of the Merger in accordance with their terms and without the exercise of discretion. The PSUs were not previously reported as the number of shares underlying the PSUs was not determinable. Pursuant to the terms of the Merger Agreement, the PSUs were cancelled in the Merger and converted into the right to receive a cash payment of $583,327.50, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock issuable in settlement of the PSUs, by (y) the offer price ($10.50). |